Homepage Top Section1

The pharma giant filed two new drug applications (NDAs) with the regulator covering the two forms of tafamidis – meglumine salt and free acid. The company said that

Sylvant secured approval in over 40 countries to treat idiopathic multicentric Castleman’s disease (iMCD), which is a subtype of Castleman disease or giant lymph node hyperplasia, lymphoid hamartoma,

Crizanlizumab (SEG101) is a humanized anti-P-selectin monoclonal antibody being studied to restrict VOCs in SCD. The status has been provided based on positive data from the phase II

Catalent will use the investment to enhance drug substance manufacturing capacity and drug product fill/finish capacity at its biologics manufacturing sites in Madison of Wisconsin and Bloomington of

As per the agreement, US-based Gilead will buy worldwide rights, with the exception of South Korea, to develop and commercialize novel small molecules against two undisclosed targets. In

Alopecia areata is a chronic autoimmune skin disease, which makes hair loss on the scalp, face and body.  At present, there are no approved therapies for this autoimmune

The dug will be produced at the group’s Topical manufacturing facility at Ahmedabad in Gujarat, India. This combination medication, according to the pharma company, is used to treat

Scars caused by eye infection or trauma convert the usually transparent cornea into an opaque state, thereby leading to blurred vision or complete blindness. Compared with existing standard

The SOLO-3 late-stage trial, which evaluated the efficacy and safety of Lynparza, featured 266 patients whose ovarian cancer relapsed following two or more lines of treatment. Patients were